XML 34 R24.htm IDEA: XBRL DOCUMENT v3.21.2

REVENUES (Tables)

9 Months Ended

Sep. 30, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenues

Revenues were as follows:

						Three Months Ended September 30, 2021																								Three Months Ended September 30, 2020
(in millions)						U.S.						Europe						Other International						Total						U.S.						Europe						Other International						Total
Product Sales:
HIV
Atripla						$	21					$	2					$	4					$	27					$	99					$	5					$	9					$	113
Biktarvy						1,875						254						147						2,276						1,584						194						113						1,891
Complera/Eviplera						28						31						5						64						26						35						9						70
Descovy						355						42						36						433						424						49						35						508
Genvoya						576						100						68						744						669						116						61						846
Odefsey						275						112						12						399						309						116						12						437
Stribild						28						11						3						42						27						13						2						42
Truvada						55						5						7						67						492						6						11						509
Revenue share - Symtuza(1)						86						41						3						130						82						34						2						118
Other HIV(2)						3						4						—						7						10						1						2						13
Total HIV						3,302						602						285						4,189						3,722						569						256						4,547
Hepatitis C virus (“HCV”)
Ledipasvir/Sofosbuvir(3)						14						5						26						45						36						11						37						84
Sofosbuvir/Velpatasvir(4)						173						77						82						332						170						74						86						330
Other HCV(5)						37						12						3						52						35						13						2						50
Total HCV						224						94						111						429						241						98						125						464
Hepatitis B virus (“HBV”) / Hepatitis Delta virus (“HDV”)
Vemlidy						103						9						96						208						99						8						70						177
Viread						1						7						18						26						3						8						21						32
Other HBV/HDV(6)						—						13						—						13						—						2						—						2
Total HBV/HDV						104						29						114						247						102						18						91						211
Veklury						1,527						109						287						1,923						785						60						28						873
Cell Therapy
Tecartus						35						12						—						47						5						4						—						9
Yescarta						100						66						9						175						85						51						2						138
Total Cell Therapy						135						78						9						222						90						55						2						147
Trodelvy						100						1						—						101						—						—						—						—
Other
AmBisome						7						67						69						143						18						58						35						111
Letairis						46						—						—						46						78						—						—						78
Zydelig						6						7						—						13						8						9						—						17
Other(7)						28						10						5						43						32						10						3						45
Total Other						87						84						74						245						136						77						38						251
Total product sales						5,479						997						880						7,356						5,076						877						540						6,493
Royalty, contract and other revenues						30						34						1						65						24						60						—						84
Total revenues						$	5,509					$	1,031					$	881					$	7,421					$	5,100					$	937					$	540					$	6,577

						Nine Months Ended September 30, 2021																								Nine Months Ended September 30, 2020
(in millions)						U.S.						Europe						Other International						Total						U.S.						Europe						Other International						Total
Product Sales:
HIV
Atripla						$	96					$	10					$	12					$	118					$	275					$	17					$	19					$	311
Biktarvy						4,926						707						461						6,094						4,346						528						314						5,188
Complera/Eviplera						73						104						12						189						77						124						17						218
Descovy						994						128						105						1,227						1,124						156						103						1,383
Genvoya						1,633						306						184						2,123						1,927						376						183						2,486
Odefsey						773						336						39						1,148						851						341						36						1,228
Stribild						94						33						12						139						100						42						12						154
Truvada						268						18						24						310						1,245						20						37						1,302
Revenue share - Symtuza(1)						261						125						8						394						244						112						6						362
Other HIV(2)						14						9						12						35						24						4						21						49
Total HIV						9,132						1,776						869						11,777						10,213						1,720						748						12,681
HCV
Ledipasvir/Sofosbuvir(3)						63						24						76						163						113						26						124						263
Sofosbuvir/Velpatasvir(4)						649						234						272						1,155						646						253						330						1,229
Other HCV(5)						97						64						9						170						100						37						12						149
Total HCV						809						322						357						1,488						859						316						466						1,641
HBV / HDV
Vemlidy						266						25						298						589						248						22						194						464
Viread						8						22						55						85						10						27						100						137
Other HBV/HDV(6)						1						29						—						30						9						6						—						15
Total HBV/HDV						275						76						353						704						267						55						294						616
Veklury						2,763						761						684						4,208						785						60						28						873
Cell Therapy
Tecartus						94						25						—						119						5						5						—						10
Yescarta						300						188						25						513						283						144						7						434
Total Cell Therapy						394						213						25						632						288						149						7						444
Trodelvy						261						1						—						262						—						—						—						—
Other
AmBisome						32						202						186						420						46						166						113						325
Letairis						157						—						—						157						241						—						—						241
Ranexa						5						—						—						5						9						—						—						9
Zydelig						22						27						1						50						24						30						1						55
Other(7)						82						41						22						145						103						32						7						142
Total Other						298						270						209						777						423						228						121						772
Total product sales						13,932						3,419						2,497						19,848						12,835						2,528						1,664						17,027
Royalty, contract and other revenues						70						140						3						213						55						170						16						241
Total revenues						$	14,002					$	3,559					$	2,500					$	20,061					$	12,890					$	2,698					$	1,680					$	17,268

_______________________________

(1)     Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(2)     Includes Emtriva and Tybost.

(3)     Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4)     Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5)     Includes Vosevi and Sovaldi.

(6)     Includes Hepcludex and Hepsera.

(7)     Includes Cayston and Jyseleca.

Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:

						Three Months Ended												Nine Months Ended
						September 30,												September 30,
(as a percentage of total revenues)						2021						2020						2021						2020
AmerisourceBergen Corporation						25		%				30		%				24		%				25		%
Cardinal Health, Inc.						22		%				19		%				21		%				22		%
McKesson Corporation						21		%				22		%				18		%				22		%

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration